4 Results for "

ALK-IN-33

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "ALK-IN-33" in MCE Product Catalog:

Cat. No.: HY-180818
Research Areas:  

Cancer

ALK-IN-33 (Compound 8q) is an orally active ALK inhibitor with an IC50 of 1.61 nM. ALK-IN-33 exhibits significant selective killing effect on ALK-positive cancer cells. ALK-IN-33 induces cell cycle arrest and apoptosis, effectively weakening the migration, invasion and long-term survival ability of cancer cells. ALK-IN-33 can be used for research on non-small cell lung cancer
loading...
    loading...
Cat. No.: HY-123689
CAS No.: 852626-89-2
Purity:  99.04%
Synonyms: ALKS-33; RDC-0313
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo. Samidorphan can improve the behavior of depressed animals .
loading...
    loading...
Cat. No.: HY-123689S
Synonyms: ALKS-33-d4; RDC-0313-d4
Samidorphan-d4 is the deuterium labeled Samidorphan(HY-123689).Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo .
loading...
    loading...
Cat. No.: HY-123689R
CAS No.: 852626-89-2
Synonyms: ALKS-33 (Standard); RDC-0313 (Standard)
Research Areas:  

Neurological Disease

Samidorphan (Standard) is the analytical standard of Samidorphan. This product is intended for research and analytical applications. Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo. Samidorphan can improve the behavior of depressed animals.
loading...
    loading...